within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB07_InterferonBeta1a;
model InterferonBeta1a 
   extends Pharmacolibrary.Drugs.ATC.L.L03AB07;

  annotation(Documentation(
    info ="<html><body><p>Interferon beta-1a is a recombinant form of human interferon beta, used primarily in the treatment of relapsing forms of multiple sclerosis (MS). It is approved by regulatory agencies such as the FDA and EMA for MS to reduce frequency of relapses and slow progression of physical disability.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for healthy volunteers and MS patients after single subcutaneous or intramuscular administration.</p><h4>References</h4><ol><li><p>Zhao, Y, Mokliatchouk, O, Ramia, NF, Naylor, ML, &amp; Butts, CL (2022). Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon β-1a phase 1 study. <i>Med (New York, N.Y.)</i> 3(9) 612–621.e3. DOI:<a href=&quot;https://doi.org/10.1016/j.medj.2022.06.006&quot;>10.1016/j.medj.2022.06.006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35853458/&quot;>https://pubmed.ncbi.nlm.nih.gov/35853458</a></p></li><li><p>Zhao, Y, Chen, K, Ramia, N, Sahu, S, Kumar, A, Naylor, ML, Zhu, L, Naik, H, &amp; Butts, CL (2021). Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers. <i>Therapeutic advances in neurological disorders</i> 14 1756286420975227–None. DOI:<a href=&quot;https://doi.org/10.1177/1756286420975227&quot;>10.1177/1756286420975227</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33628334/&quot;>https://pubmed.ncbi.nlm.nih.gov/33628334</a></p></li><li><p>Siddiqui, MA, &amp; Wellington, K (2005). Intramuscular interferon-beta-1a: in patients at high risk of developing clinically definite multiple sclerosis. <i>CNS drugs</i> 19(1) 55–64. DOI:<a href=&quot;https://doi.org/10.2165/00023210-200519010-00005&quot;>10.2165/00023210-200519010-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15651905/&quot;>https://pubmed.ncbi.nlm.nih.gov/15651905</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end InterferonBeta1a;
